Brief: U.S. FDA Accepts Takeda's Application For Intravenous Entyvio® (Vedolizumab) In Pediatric Ulcerative Colitis And Crohn's Disease
09/06/2026 21:40
BRIEF-U.S. FDA Accepts Takeda's Application For Intravenous Entyvio® (Vedolizumab) In Pediatric Ulcerative Colitis And Crohn's Disease June 9 (Reuters) - Takeda Pharmaceutical Co Ltd 4502.T:
U.S. FDA ACCEPTS TAKEDA'S APPLICATION FOR INTRAVENOUS ENTYVIO® (VEDOLIZUMAB) IN PEDIATRIC ULCERATIVE COLITIS AND CROHN'S DISEASE
TAKEDA PHARMACEUTICAL CO - FDA SETS PDUFA GOAL DATE IN Q1 2027 FOR ENTYVIO APPLICATION
Source text: ID:nBwb9nn9a
Further company coverage: 4502.T
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Takeda Pharmaceutical Co
See all newsBrief: Takeda Says Zasocitinib Significantly Outperforms Deucravacitinib In Head-To-Head Phase 3 Psoriasis Study
Takeda's AI-crafted psoriasis pill tops Bristol Myers' Sotyktu in head-to-head trial
Brief: U.S. FDA Accepts Takeda's Application For Intravenous Entyvio® (Vedolizumab) In Pediatric Ulcerative Colitis And Crohn's Disease
Recorded 402.5 Billion Yen Additional Provision For Legal Proceedings After U.S. Jury Verdict In Antitrust Litigation
Table: Takeda Pharma -2025/26 parent results